Darwin Ye

Darwin Ye is a Biotech Analyst and Associate Director at UBS Asset Management, where they focus on global healthcare including biotech and pharmaceuticals. Previously, they contributed significantly to the Abramson Cancer Center at Penn, leading high-impact studies in immuno-oncology, which resulted in publications in top journals such as Cell and Science. Darwin's work includes launching a Phase 2 lung cancer trial in collaboration with Merck, and aiding in the development of technology for CAR-T therapy, which helped establish Dispatch Bio. They were also a Parker Scholar at the Parker Institute for Cancer Immunotherapy, recognized as one of nine awardees sharing a $4.5 million total award for innovative cancer immunotherapy research. Darwin holds a Ph.D. in Cancer Biology from the University of Pennsylvania and completed a Mini-MBA from The Wharton School.